<DOC>
	<DOCNO>NCT01497002</DOCNO>
	<brief_summary>Improvement treatment-results elderly patient acute myeloid leukemia intensification consolidation chemotherapy and/or allografting consolidative immunotherapy</brief_summary>
	<brief_title>Comparison OSHO Protocol Standard Arm Protocol German AML Intergroup Patients With AML &gt; 60a</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Patients sexes age &gt; 60 year newly diagnose acute myeloid leukaemia define new WHO classification write informed consent pretreatment leukemia inform consent simultaneous inclusion study mental disability contraindication intensive chemotherapy AML FAB M3 contraindication allogeneic stem cell transplantation restriction follow organ function : creatinineclearance &lt; 50 ml/min cardiac ejection fraction &lt; 40 % severe pulmonary restriction bilirubin &gt; 2x ULN ; SGOT SGPT &gt; 4x ULN uncontrolled hypertension severe uncontrolled metabolism disturbance Karnofskyperformancescore &lt; 70 % hepatitis C malignancy age unrelated donor &gt; 70 year age relate donor &gt; 75 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>AML</keyword>
</DOC>